Linking Phenotypes and Modes of Action Through High-Content Screen Fingerprints

Assay and Drug Development Technologies

Volumn 13, Issue 7, 2015, Pages 415-427

  Reisen, Felix ^a   Sauty De Chalon, Amelie ^a   Pfeifer, Martin ^a   Zhang, Xian ^a   Gabriel, Daniela ^a   Selzer, Paul ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BELINOSTAT; CHEMBL 1205806; DNA TOPOISOMERASE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KF 38789; MAMMALIAN TARGET OF RAPAMYCIN; MXSELECTIN 2105; NOCODAZOLE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PITAVASTATIN; PROTEIN KINASE B; SELECTIN ANTAGONIST; SILMITASERTIB; SIMVASTATIN; TUBULIN; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; TARGET OF RAPAMYCIN KINASE; TUBULIN MODULATOR;

ARTICLE; CELL NUCLEUS; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOPLASM; CYTOSKELETON; ENDOPLASMIC RETICULUM; FINGER DERMATOGLYPHICS; GOLGI COMPLEX; HIGH CONTENT SCREEN FINGERPRINT; INTRACELLULAR SPACE; MICROTUBULE; PHENOTYPE; ANTAGONISTS AND INHIBITORS; HIGH THROUGHPUT SCREENING; HUMAN; PROCEDURES;

HIGH-THROUGHPUT SCREENING ASSAYS; HISTONE DEACETYLASE INHIBITORS; HUMANS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; TOR SERINE-THREONINE KINASES; TUBULIN MODULATORS;

EID: 84940654987     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.656     Document Type: Article

References (55)

1. Swinney DC, Anthony J: How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-519.
2. Bickle M: The beautiful cell: high-content screening in drug discovery. Anal Bioanal Chem 2010;398:219-226.
3. Mackay-Sim A: Patient-derived stem cells: pathways to drug discovery for brain diseases. Front Cell Neurosci 2013;7:1-10.
4. Lomenick B, Jung G, Wohlschlegel JA, Huang J: Target identification using drug affinity responsive target stability (DARTS). Curr Protoc Chem Biol 2011;3:163-180.
5. Lomenick B, Olsen RW, Huang J: Identification of direct protein targets of small molecules. ACS Chem Biol 2011;6:34-46.
6. Smith AM, Heisler LE, St Onge RP, et al.: Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples. Nucleic Acids Res 2010;38:e142.
7. Lounkine E, Keiser MJ, Whitebread S, et al.: Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012;486:361-367.
8. Keiser MJ, Setola V, Irwin JJ, et al.: Predicting new molecular targets for known drugs. Nature 2009;462:175-181.
9. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL: Global mapping of pharmacological space. Nat Biotechnol 2006;24:805-815.
10. Reutlinger M, Koch CP, Reker D, et al.: Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for 'Orphan' Molecules. Mol Inform 2013;32:133-138.
11. Lamb J, Crawford ED, Peck D, et al.: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935.
12. Sirota M, Dudley JT, Kim J, et al.: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011;3:96ra77.
13. Young DW, Bender A, Hoyt J, et al.: Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 2008;4:59-68.
14. Feng Y, Mitchison TJ, Bender A, Young DW, Tallarico JA: Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov 2009;8:567-578.
15. Loo LH, Wu LF, Altschuler SJ: Image-based multivariate profiling of drug responses from single cells. Nat Methods 2007;4:445-453.
16. Perlman ZE, Slack MD, Feng Y, et al.: Multidimensional drug profiling by automated microscopy. Science 2004;306:1194-1198.
17. Adams CL, Kutsyy V, Coleman DA, et al.: Compound classification using image-based cellular phenotypes. Methods Enzymol 2006;414:440-468.
18. Barabasz A, Foley B, Otto JC, Scott A, Rice J: The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action. Assay Drug Dev Technol 2006;4:153-163.
19. Ljosa V, Caie PD, Ter Horst R, et al.: Comparison of methods for image-based profiling of cellular morphological responses to small-molecule treatment. J Biomol Screen 2013;18:1321-1329.
20. Gaulton A, Bellis LJ, Bento AP, et al.: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012;40:D1100-D1107.
21. Wassermann AM, Lounkine E, Glick M: Bioturbo similarity searching: combining chemical and biological similarity to discover structurally diverse bioactive molecules. J Chem Inf Model 2013;53:692-703.
22. Caie PD, Walls RE, Ingleston-Orme A, et al.: High-content phenotypic profiling of drug response signatures across distinct cancer cells. Mol Cancer Ther 2010;9:1913-1926.
23. perkinelmer: www.perkinelmer.com (Last accessed on June 24, 2015).
24. Van Dongen S: Graph clustering via a discrete uncoupling process. Siam J Matrix Anal Appl 2008;30:121-141.
25. Shannon P, Markiel A, Ozier O, et al.: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-2504.
26. Knox C, Law V, Jewison T, et al.: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011;39:D1035-D1041.
27. gostardb: www.gostardb.com/gostar/ (Last accessed on June 24, 2015).
28. thomsonreuters: www.thomsonreuters.com (Last accessed on June 24, 2015).
29. Geer LY, Marchler-Bauer A, Geer RC, et al.: The NCBI BioSystems database. Nucleic Acids Res 2010;38:D492-D496.
30. Ashburner M, Ball CA, Blake JA, et al.: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-29.
31. Pommier Y, Pourquier P, Fan Y, Strumberg D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:83-105.
32. Fedorko ME, Hirsch JG, Cohn ZA: Autophagic vacuoles produced in vitro. J Cell Biol 1968;38:377-391.
33. Geng Y, Kohli L, Klocke BJ, Roth KA: Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 2010;12:473-481.
34. Hoebeke J, Van Nijen G, De Brabander M: Interaction of oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. Biochem Biophys Res Commun 1976;69:319-324.
35. Sausville EA, Tomaszewski JE, Ivy P: Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-383.
36. Taiyab A, Sreedhar AS, Rao Ch M: Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. Biochem Pharmacol 2009;78:142-152.
37. Klausner RD, Donaldson JG, Lippincottschwartz J: Brefeldin-a - insights into the control of membrane traffic and organelle structure. J Cell Biol 1992;116:1071-1080.
38. Plumb JA, Finn PW, Williams RJ, et al.: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-728.
39. Richon VM: Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 2006;95:S2-S6.
40. Ohta S, Inujima Y, Abe M, et al.: Inhibition of P-selectin specific cell adhesion by a low molecular weight, non-carbohydrate compound, KF38789. Inflamm Res 2001;50:544-551.
41. Kemnitzer W, Drewe J, Jiang S, et al.: Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7,8-positions. J Med Chem 2007;50:2858-2864.
42. Mallon R, Feldberg LR, Lucas J, et al.: Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 2011;17:3193-3203.
43. Fan QW, Knight ZA, Goldenberg DD, et al.: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-349.
44. Fan QW, Cheng C, Hackett C, et al.: Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010;3:ra81.
45. Herzog A, Bian Y, Vander Broek R, et al.: PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 2013;19:3808-3819.
46. Greshock J, Bachman KE, Degenhardt YY, et al.: Molecular target class is predictive of in vitro response profile. Cancer Res 2010;70:3677-3686.
47. Billich A: Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 2007;10:53-59.
48. Cai X, Xu Y, Cheung AK, et al.: PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling. Chem Biol 2013;20:912-921.
49. Coppola GM, Damon RE, Yu H, Engstrom RG, Scallen TJ: Design and biological evaluation of a series of thiophene-based 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Bioorg Med Chem Lett 1997;7:549-554.
50. Salas Solana J, Almansa Rosales C, Soliva Soliva R, et al.: Purine Derivatives, 2008. (patent WO 2008/090181 A1)
51. Siddiqui-Jain A, Drygin D, Streiner N, et al.: CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010;70:10288-10298.
52. Guerra B, Issinger OG: Protein kinase CK2 in human diseases. Curr Med Chem 2008;15:1870-1886.1
53. Barretina J, Caponigro G, Stransky N, et al.: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-607.
54. Goeman JJ, Buhlmann P: Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics 2007;23:980-987.
55. Khatri P, Sirota M, Butte AJ: Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol 2012;8:e1002375.